Shanghai SynTheAll Pharmaceuticals Co. LTD. DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

Virtual Booth

Contact Supplier

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

Interview #SpeakPharma, Vlog #PharmaReel, Data Compilation #PharmaFlow, 174 News #PharmaBuzz

media
Interview #SpeakPharma
Vlog #PharmaReel
Data Compilation #PharmaFlow
174 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

28 All APIs, 18 USDMF, 4 KDMF, 7 NDC API

28 All APIs
18 USDMF
4 KDMF
7 NDC API

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

INSPECTIONS & REGISTRATIONS

16 FDA, 5 EDQM

inspections
16 FDA
5 EDQM

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Established in December 2000, WuXi AppTec (NYSE: WX) is a leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and the United States. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. Our services are designed to help our worldwide customers shorten the discovery an...

CPhI North America CPhI North America

Not Confirmed

Not Confirmed

20-22 May, 2025

Pennsylvania Conv Center, Philadelphia
ArvoArvo

Not Confirmed

Not Confirmed

04-08 May, 2025

Salt Lake City, UT
SynBioBetaSynBioBeta

Not Confirmed

Not Confirmed

05-08 May, 2025

San Jose Convention Center, CA

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

Country

China

Address

WuXi AppTec 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131, Ch...

Telephone

enquiries@pharmacompass.com

Website

http://www.wuxiapptec.com/

YouTube

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]

🎙️Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

Impressions: 214

VLOG #PharmaReel

[Sponsored by another company]

🎥T-MAX™ 3-in-1 Formula: For Next-Gen E-Liquids

Impressions: 204

DATA COMPILATION #PharmaFlow

[Sponsored by another company]

Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.

Impressions: 3947

NEWS #PharmaBuzz

WuXi AppTec sells US device testing business to NAMSA

18 Jan 2025

// FIERCE BIOTECH

WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative

12 Jan 2025

// PR NEWSWIRE

WuXi AppTec's Couvet Site Earns EcoVadis 2024 Silver Medal

14 Nov 2024

// PR NEWSWIRE

Wuxi Apptec Named Global Crdmo Company Of The Year Again

29 Oct 2024

// PR NEWSWIRE

WuXi AppTec Maintains AA MSCI ESG Rating For Fourth Consecutive Year

01 Sep 2024

// PR NEWSWIRE

US clinical trials in China questioned by US lawmakers

21 Aug 2024

// REUTERS

ALL APIs

Click the button for full data set

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Only 10 entries up to this point, click to access all

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Upload your audits for free, ask us

FDA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EDQM

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Contact Shanghai SynTheAll Pharmaceuticals Co. LTD. and get a quotation

Shanghai SynTheAll Pharmaceuticals Co. LTD. is a supplier offers 27 products (APIs, Excipients or Intermediates).

Find a price of Exatecan bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of Mafodotin [Usan] bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of Monomethyl Auristatin E bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of 2'-OME A(BZ) AMIDITE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of 2'-MOE T AMIDITE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of MC-VC-PAB-MMAE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of MORPHOLINO GUANINE PHOSPHORAMIDOCHLORIDATE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of VAL-CIT-PAB-MMAE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of 2'-OME G(IBU) AMIDITE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of 2'-MOE MEC(BZ) AMIDITE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of CPG OLIGONUCLEOTIDE 1018 bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of PAYLOAD-LINKER VCMMAE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of 2'-OME U AMIDITE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of 2' -MOE A(BZ) AMIDITE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of 2'-MOE G(IBU) AMIDITE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of MORPHOLINO THYMINE PHOSPHORAMIDOCHLORIDATE bulk with DMF offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of WUXI ADHERENT HEK293T (WAHT) bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of LENTIVIRAL VECTOR bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of 1613220-15-7 bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of Elexacaftor bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of Enavogliflozin bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of Ivacaftor bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of Roxadustat bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of Sparsentan bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of Telotristat Etiprate bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of Tezacaftor bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Find a price of Zanubrutinib bulk offered by Shanghai SynTheAll Pharmaceuticals Co. LTD.

Company profile for WuXi AppTec